Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Subscribe To Our Newsletter & Stay Updated
